著作: [福田 達也]/Oku Naoto/[小暮 健太朗]/Application and utility of liposomal neuroprotective agents and biomimetic nanoparticles for the treatment of ischemic stroke/[Pharmaceutics]
ヘルプを読む
「著作」（著作（著書，論文，レター，国際会議など））は，研究業績にかかる著作（著書，論文，レター，国際会議など）を登録するテーブルです． (この情報が属するテーブルの詳細な定義を見る)
- 項目名の部分にマウスカーソルを置いて少し待つと，項目の簡単な説明がツールチップ表示されます．
編集する
複製して登録
削除する| 種別 | 必須 | 総説·解説 | |||
|---|---|---|---|---|---|
| 言語 | 必須 | 英語 | |||
| 招待 | 推奨 | ||||
| 審査 | 推奨 | ||||
| カテゴリ | 推奨 | ||||
| 共著種別 | 推奨 | ||||
| 学究種別 | 推奨 | ||||
| 組織 | 推奨 | ||||
| 著者 | 必須 | ||||
| 題名 | 必須 |
(英) Application and utility of liposomal neuroprotective agents and biomimetic nanoparticles for the treatment of ischemic stroke |
|||
| 副題 | 任意 | ||||
| 要約 | 任意 |
(英) Ischemic stroke is still one of the leading causes of high mortality and severe disability worldwide. Therapeutic options for ischemic stroke and subsequent cerebral ischemia/reperfusion injury remain limited due to challenges associated with drug permeability through the blood-brain barrier (BBB). Neuroprotectant delivery with nanoparticles, including liposomes, offers a promising solution to address this problem, as BBB disruption following ischemic stroke allows nanoparticles to pass through the intercellular gaps between endothelial cells. To ameliorate ischemic brain damage, a number of nanotherapeutics encapsulating neuroprotective agents, as well as surface-modified nanoparticles with specific ligands targeting the injured brain regions, have been developed. Combination therapy with nanoparticles encapsulating neuroprotectants and tissue plasminogen activator (t-PA), a globally approved thrombolytic agent, has been demonstrated to extend the narrow therapeutic time window of t-PA. In addition, the design of biomimetic drug delivery systems (DDS) employing circulating cells (e.g., leukocytes, platelets) with unique properties has recently been investigated to overcome the injured BBB, utilizing these cells' inherent capability to penetrate the ischemic brain. Herein, we review recent findings on the application and utility of nanoparticle DDS, particularly liposomes, and various approaches to developing biomimetic DDS functionalized with cellular membranes/membrane proteins for the treatment of ischemic stroke. |
|||
| キーワード | 推奨 | ||||
| 発行所 | 推奨 | ||||
| 誌名 | 必須 |
Pharmaceutics(Molecular Diversity Preservation International)
(pISSN: 1999-4923)
|
|||
| 巻 | 必須 | 14 | |||
| 号 | 必須 | 2 | |||
| 頁 | 必須 | 361 361 | |||
| 都市 | 任意 | ||||
| 年月日 | 必須 | 2022年 2月 4日 | |||
| URL | 任意 | ||||
| DOI | 任意 | 10.3390/pharmaceutics14020361 (→Scopusで検索) | |||
| PMID | 任意 | 35214092 (→Scopusで検索) | |||
| CRID | 任意 | ||||
| WOS | 任意 | ||||
| Scopus | 任意 | ||||
| 評価値 | 任意 | ||||
| 被引用数 | 任意 | ||||
| 指導教員 | 推奨 | ||||
| 備考 | 任意 |
|
|||